New NHS drugs policy could see elderly denied treatment
The National Institute for Health and Care Excellence is due to change how it decides which drugs can be provided by the health service
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.New drugs will only be made available on the NHS if they help people deemed to be a benefit to society under proposals that prompted fears elderly people could be denied treatment.
The National Institute for Health and Care Excellence (Nice) is due to change how it decides which drugs can be provided by the health service.
The proposals would mean Nice would have to consider “wider societal benefits” of the treatments as well as the cost and benefits to patients.
Dr Paul Catchpole, of the Association of the British Pharmaceutical Industry, told The Daily Telegraph: “It is concerning because, under the new appraisal system, cancer medicine might do less well because older people aren't as beneficial to society.
"You might have a cancer treatment for a severe disease but because the majority of the cancer patients are elderly they aren't generating wider societal benefits, they are more likely to be generating costs.
“But if you have got a medicine that gets someone back to work then you could argue, under this system, that that's better for society.”
David Taylor, professor of pharmaceutical and public health policy at University College London, said the plan was “a real threat to the public well-being and a real threat to the well-being of older people”.
“To me the whole methodology seems deeply suspect,” he said.
Sources close to Health Secretary Jeremy Hunt told The Telegraph that plan was at an early stage and would not result in discrimination against elderly people.
The draft policy is due to be put out for public consultation in the next few weeks.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments